SMMT Insider Trading

Insider Ownership Percentage: 88.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Summit Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Summit Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$400M-$200M$0$200M$400MTotal Insider BuyingTotal Insider Selling

Summit Therapeutics Share Price & Price History

Current Price: $20.32
Price Change: Price Decrease of -0.28 (-1.36%)
As of 03/28/2025 05:00 PM ET

This chart shows the closing price history over time for SMMT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$20.32Closing price on 03/29/25:

SEC Filings (Institutional Ownership Changes) for Summit Therapeutics (NASDAQ:SMMT)

4.61% of Summit Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at SMMT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$149Mbought$34MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100M$0$100MTotal InflowsTotal Outflows
Summit Therapeutics logo
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.
Read More on Summit Therapeutics

Today's Range

Now: $20.32
Low: $20.10
High: $21.08

50 Day Range

MA: $20.51
Low: $17.78
High: $24.65

52 Week Range

Now: $20.32
Low: $2.10
High: $33.89

Volume

1,685,854 shs

Average Volume

3,430,026 shs

Market Capitalization

$14.99 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Summit Therapeutics?

Summit Therapeutics' top insider investors include:
  1. Manmeet Singh Soni (COO)
  2. Mahkam Zanganeh (CEO)
  3. Ankur Dhingra (CFO)
Learn More about top insider investors at Summit Therapeutics.

Who are the major institutional investors of Summit Therapeutics?

Summit Therapeutics' top institutional shareholders include:
  1. Vanguard Group Inc. — 1.58%
  2. FMR LLC — 1.09%
  3. Price T Rowe Associates Inc. MD — 0.89%
  4. Geode Capital Management LLC — 0.43%
  5. Charles Schwab Investment Management Inc. — 0.20%
  6. Pictet Asset Management Holding SA — 0.19%
Learn More about top institutional investors of Summit Therapeutics stock.

Which major investors are selling Summit Therapeutics stock?

During the previous quarter, SMMT stock was sold by these institutional investors:
  1. Citadel Advisors LLC
  2. Susquehanna International Group LLP
  3. FMR LLC
  4. Group One Trading LLC
  5. Wolverine Trading LLC
  6. GTS Securities LLC
  7. Jane Street Group LLC
  8. Handelsbanken Fonder AB

Which major investors are buying Summit Therapeutics stock?

In the previous quarter, SMMT stock was purchased by institutional investors including:
  1. Price T Rowe Associates Inc. MD
  2. Vanguard Group Inc.
  3. Pictet Asset Management Holding SA
  4. BNP Paribas Financial Markets
  5. Invesco Ltd.
  6. Twin Tree Management LP
  7. Boxer Capital Management LLC
  8. Polymer Capital Management HK LTD
Within the last year, these company insiders have bought Summit Therapeutics stock:
  1. Manmeet Singh Soni (COO)
  2. Mahkam Zanganeh (CEO)
  3. Ankur Dhingra (CFO)
Learn More investors buying Summit Therapeutics stock.